Luminus Management’s PTC Therapeutics PTCT Stock Holding History

Luminus Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-195,000	Closed	-$6.59M	–	112
2019 Q3	$6.59M	Buy	+195,000	New	+$8.49M	0.19%	71

Other funds holding PTCT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Luminus Management's PTCT Position: Q4 2019 in Review

Luminus Management sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 195,000 shares — an estimated $6.59M sold.

Luminus Management first reported a position in PTCT in Q3 2019 and held it in 1 quarter. The position peaked at $6.59M in Q3 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

Luminus Management reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
Luminus Management sold 195,000 PTC Therapeutics shares in Q4 2019, an estimated $6.59M.
Luminus Management first reported a position in PTC Therapeutics in Q3 2019 and held it in 1 quarter.
Luminus Management's PTC Therapeutics position peaked at $6.59M in Q3 2019.
206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Luminus Management's 13F filing for Q4 2019, filed 14 Feb 2020.